Narrowing the Scope: PARP Inhibitor Restrictions in Ovarian Cancer

The landscape of gynecologic oncology is rapidly shifting toward a precision-based approach, where treatment decisions are increasingly dictated by a tumor's molecular fingerprint. In 2026, the focus has moved beyond general chemotherapy toward personalized maintenance strategies that utilize biomarkers like homologous recombination deficiency and proficient mismatch repair to predict patient response.

In an interview with Targeted Oncology, Erin Crane, MD, MPH, discusses PARP inhibitor restrictions in gynecologic oncology.

Watch part 1 of the interview here.